Yufeng Hu
First author of a 2026 Circulation study identifying LAPTM4A as a novel mTORC1 activator driving pathological cardiac hypertrophy
Gannan Innovation and Translational Medicine Research Institute, School of Pharmacy, First Affiliated Hospital, Gannan Medical University, Ganzhou, China
Portrait: Gannan Medical University
Yufeng Hu is affiliated with the Gannan Innovation and Translational Medicine Research Institute at the First Affiliated Hospital of Gannan Medical University in Ganzhou, China. No further public biographical details were found.
Hu is first author of a 2026 Circulation study that screened lysosomal genes in cardiomyocytes and identified LAPTM4A as a novel booster of mTORC1 signaling, driving pathological cardiac hypertrophy through NEDD4L-mediated AKT ubiquitination.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | Novel mTORC1 Booster LAPTM4A Potentiates Pathological Cardiac Hypertrophy HU2026 First author identifying LAPTM4A as a novel driver of mTORC1-dependent pathological cardiac hypertrophy in mice and rats. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Yufeng Hu.
ShowHide
- Hongliang Li Vice President of Gannan Medical University and Executive Director of its State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases; researcher of cardiovascular and metabolic diseases
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.